Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy

Molecular Therapy

Volumn 25, Issue 1, 2017, Pages 232-248

  Kamran, Neha ^a   Kadiyala, Padma ^a   Saxena, Meghna ^a   Candolfi, Marianela ^b   Li, Youping ^a   Moreno Ayala, Mariela A ^a,b   Raja, Nicholas ^a   Shah, Diana ^a   Lowenstein, Pedro R ^a   Castro, Maria G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

gene therapy; glioma; immunotherapy; myeloid cells; tumor microenvironment

Indexed keywords

ARGINASE; B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLT3 LIGAND; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4 RECEPTOR ALPHA; PROGRAMMED DEATH 1 LIGAND 1; SITIMAGENE CERADENOVEC; BIOLOGICAL MARKER; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CULTURE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DEPLETION; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM SURVIVAL; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; BRAIN TUMOR; CELL CULTURE; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; GENETICS; GLIOMA; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION; TRANSGENE;

ANIMALS; B7-H1 ANTIGEN; BIOMARKERS; BONE MARROW CELLS; BRAIN NEOPLASMS; CELLS, CULTURED; CTLA-4 ANTIGEN; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENE EXPRESSION; GENETIC THERAPY; GLIOMA; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; T-LYMPHOCYTE SUBSETS; THYMIDINE KINASE; TRANSGENES; TUMOR MICROENVIRONMENT;

EID: 85016267607     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.10.003     Document Type: Article

References (69)

1. 1 Ostrom, Q.T., Bauchet, L., Davis, F.G., Deltour, I., Fisher, J.L., Langer, C.E., Pekmezci, M., Schwartzbaum, J.A., Turner, M.C., Walsh, K.M., et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-oncol. 16 (2014), 896–913.
2. 2 Calinescu, A.A., Kamran, N., Baker, G., Mineharu, Y., Lowenstein, P.R., Castro, M.G., Overview of current immunotherapeutic strategies for glioma. Immunotherapy 7 (2015), 1073–1104.
3. 3 Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., Vitucci, M., Morozova, O., et al., Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 372 (2015), 2481–2498.
4. 4 Reardon, D.A., Freeman, G., Wu, C., Chiocca, E.A., Wucherpfennig, K.W., Wen, P.Y., Fritsch, E.F., Curry, W.T. Jr., Sampson, J.H., Dranoff, G., Immunotherapy advances for glioblastoma. Neuro-oncol. 16 (2014), 1441–1458.
5. 5 Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005), 987–996.
6. 6 Stupp, R., Hegi, M.E., Gilbert, M.R., Chakravarti, A., Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin. Oncol. 25 (2007), 4127–4136.
7. 7 Tanimoto, T., Hori, A., Kami, M., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med., 363, 2010, 1966 author reply 1967-1968.
8. 8 Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
9. 9 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
10. 10 Dietrich, P.Y., Dutoit, V., Walker, P.R., Immunotherapy for glioma: from illusion to realistic prospects?. Am. Soc. Clin. Oncol. Educ. Book, 2014, 51–59, 10.14694/EdBook_AM.2014.34.51.
11. 11 Jackson, C.M., Lim, M., Drake, C.G., Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res. 20 (2014), 3651–3659.
12. 12 Yang, Y., Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125 (2015), 3335–3337.
13. 13 Davies, D.C., Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J. Anat. 200 (2002), 639–646.
14. 14 Rascher, G., Fischmann, A., Kröger, S., Duffner, F., Grote, E.H., Wolburg, H., Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 104 (2002), 85–91.
15. 15 Goldmann, J., Kwidzinski, E., Brandt, C., Mahlo, J., Richter, D., Bechmann, I., T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J. Leukoc. Biol. 80 (2006), 797–801.
16. 16 Cserr, H.F., Harling-Berg, C.J., Knopf, P.M., Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 2 (1992), 269–276.
17. 17 Mineharu, Y., Muhammad, A.K., Yagiz, K., Candolfi, M., Kroeger, K.M., Xiong, W., Puntel, M., Liu, C., Levy, E., Lugo, C., et al. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics 9 (2012), 827–843.
18. 18 Ali, S., King, G.D., Curtin, J.F., Candolfi, M., Xiong, W., Liu, C., Puntel, M., Cheng, Q., Prieto, J., Ribas, A., et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res. 65 (2005), 7194–7204.
19. 19 Curtin, J.F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M.R., Michelsen, K.S., Kroeger, K.M., Liu, C., et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med., 6, 2009, e10.
20. 20 Ghulam Muhammad, A.K., Candolfi, M., King, G.D., Yagiz, K., Foulad, D., Mineharu, Y., Kroeger, K.M., Treuer, K.A., Nichols, W.S., Sanderson, N.S., et al. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res. 15 (2009), 6113–6127.
21. 21 Candolfi, M., Yagiz, K., Foulad, D., Alzadeh, G.E., Tesarfreund, M., Muhammad, A.K., Puntel, M., Kroeger, K.M., Liu, C., Lee, S., et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 15 (2009), 4401–4414.
22. 22 Candolfi, M., Yagiz, K., Wibowo, M., Ahlzadeh, G.E., Puntel, M., Ghiasi, H., Kamran, N., Paran, C., Lowenstein, P.R., Castro, M.G., Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res. 20 (2014), 1555–1565.
23. 23 Berghoff, A.S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-oncol. 17 (2015), 1064–1075.
24. 24 Bloch, O., Crane, C.A., Kaur, R., Safaee, M., Rutkowski, M.J., Parsa, A.T., Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 19 (2013), 3165–3175.
25. 25 Grossman, S.A., Ye, X., Lesser, G., Sloan, A., Carraway, H., Desideri, S., Piantadosi, S., NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 17 (2011), 5473–5480.
26. 26 Gustafson, M.P., Lin, Y., New, K.C., Bulur, P.A., O'Neill, B.P., Gastineau, D.A., Dietz, A.B., Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-oncol. 12 (2010), 631–644.
27. 27 Humphries, W., Wei, J., Sampson, J.H., Heimberger, A.B., The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg. Clin. N. Am. 21 (2010), 125–137.
28. 28 Prosniak, M., Harshyne, L.A., Andrews, D.W., Kenyon, L.C., Bedelbaeva, K., Apanasovich, T.V., Heber-Katz, E., Curtis, M.T., Cotzia, P., Hooper, D.C., Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 19 (2013), 3776–3786.
29. 29 Wu, A., Wei, J., Kong, L.Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., Heimberger, A.B., Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncol. 12 (2010), 1113–1125.
30. 30 Raychaudhuri, B., Rayman, P., Huang, P., Grabowski, M., Hambardzumyan, D., Finke, J.H., Vogelbaum, M.A., Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J. Neurooncol. 122 (2015), 293–301.
31. 31 Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E.C., Garcia, J., Vogelbaum, M.A., Finke, J., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-oncol. 13 (2011), 591–599.
32. 32 Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
33. 33 Marvel, D., Gabrilovich, D.I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125 (2015), 3356–3364.
34. 34 Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5 (2005), 641–654.
35. 35 Ezernitchi, A.V., Vaknin, I., Cohen-Daniel, L., Levy, O., Manaster, E., Halabi, A., Pikarsky, E., Shapira, L., Baniyash, M., TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177 (2006), 4763–4772.
36. 36 Hanson, E.M., Clements, V.K., Sinha, P., Ilkovitch, D., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183 (2009), 937–944.
37. 37 Kim, E.S., Kim, J.E., Patel, M.A., Mangraviti, A., Ruzevick, J., Lim, M., Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J. Immunol. Res., 2016, 2016, 4683607.
38. 38 Kane, J.R., Miska, J., Young, J.S., Kanojia, D., Kim, J.W., Lesniak, M.S., Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro-oncol. 17:Suppl 2 (2015), ii24–ii36.
39. 39 Chen, K.S., Mitchell, D.A., Monoclonal antibody therapy for malignant glioma. Adv. Exp. Med. Biol. 746 (2012), 121–141.
40. 40 Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
41. 41 Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap, E.A., Feldman, S.A., Chinnasamy, N., Kuan, C.T., Song, H., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum. Gene Ther. 23 (2012), 1043–1053.
42. 42 Ohno, M., Natsume, A., Ichiro Iwami, K., Iwamizu, H., Noritake, K., Ito, D., Toi, Y., Ito, M., Motomura, K., Yoshida, J., et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 101 (2010), 2518–2524.
43. 43 Messmer, M.N., Netherby, C.S., Banik, D., Abrams, S.I., Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol. Immunother. 64 (2015), 1–13.
44. 44 Wiesner, S.M., Decker, S.A., Larson, J.D., Ericson, K., Forster, C., Gallardo, J.L., Long, C., Demorest, Z.L., Zamora, E.A., Low, W.C., et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res. 69 (2009), 431–439.
45. 45 Calinescu, A.A., Núñez, F.J., Koschmann, C., Kolb, B.L., Lowenstein, P.R., Castro, M.G., Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J. Vis. Exp.(96), 2015, 10.3791/52443.
46. 46 Kohanbash, G., McKaveney, K., Sakaki, M., Ueda, R., Mintz, A.H., Amankulor, N., Fujita, M., Ohlfest, J.R., Okada, H., GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 73 (2013), 6413–6423.
47. 47 Scheurer, M.E., Amirian, E., Cao, Y., Gilbert, M.R., Aldape, K.D., Kornguth, D.G., El-Zein, D.G., Bondy, M.L., Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. Clin Cancer Res. 14 (2008), 6640–6646.
48. 48 Gadani, S.P., Cronk, J.C., Norris, G.T., Kipnis, J., IL-4 in the brain: a cytokine to remember. J. Immunol. 189 (2012), 4213–4219.
49. 49 Mauti, L.A., Le Bitoux, M.A., Baumer, K., Stehle, J.C., Golshayan, D., Provero, P., Stamenkovic, I., Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121 (2011), 2794–2807.
50. 50 Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M., Johnson, M.F., Lee, J.M., Elashoff, D., Strieter, R., Dubinett, S., Sharma, S., Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE, 7, 2012, e40677.
51. 51 Jacobs, J.F., Idema, A.J., Bol, K.F., Nierkens, S., Grauer, O.M., Wesseling, P., Grotenhuis, J.A., Hoogerbrugge, P.M., de Vries, I.J., Adema, G.J., Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-oncol. 11 (2009), 394–402.
52. 52 Galon, J., Angell, H.K., Bedognetti, D., Marincola, F.M., The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39 (2013), 11–26.
53. 53 Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
54. 54 Gajewski, T.F., Woo, S.R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., Spranger, S., Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 268–276.
55. 55 Trimboli, A.J., Cantemir-Stone, C.Z., Li, F., Wallace, J.A., Merchant, A., Creasap, N., Thompson, J.C., Caserta, E., Wang, H., Chong, J.L., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461 (2009), 1084–1091.
56. 56 Palumbo, A. Jr., Da Costa, Nde.O., Bonamino, M.H., Pinto, L.F., Nasciutti, L.E., Genetic instability in the tumor microenvironment: a new look at an old neighbor. Mol. Cancer, 14, 2015, 145.
57. 57 Guo, G., Marrero, L., Rodriguez, P., Del Valle, L., Ochoa, A., Cui, Y., Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res. 73 (2013), 1668–1675.
58. 58 Mlecnik, B., Bindea, G., Angell, H.K., Sasso, M.S., Obenauf, A.C., Fredriksen, T., Lafontaine, L., Bilocq, A.M., Kirilovsky, A., Tosolini, M., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med., 6, 2014, 228ra37.
59. 59 Baker, G.J., Yadav, V.N., Motsch, S., Koschmann, C., Calinescu, A.A., Mineharu, Y., Camelo-Piragua, S.I., Orringer, D., Bannykh, S., Nichols, W.S., et al. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 16 (2014), 543–561.
60. 60 Wolburg, H., Noell, S., Fallier-Becker, P., Mack, A.F., Wolburg-Buchholz, K., The disturbed blood-brain barrier in human glioblastoma. Mol. Aspects Med. 33 (2012), 579–589.
61. 61 On, N.H., Mitchell, R., Savant, S.D., Bachmeier, C.J., Hatch, G.M., Miller, D.W., Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J. Neurooncol. 111 (2013), 133–143.
62. 62 Dubois, L.G., Campanati, L., Righy, C., D'Andrea-Meira, I., Spohr, T.C., Porto-Carreiro, I., Pereira, C.M., Balça-Silva, J., Kahn, S.A., DosSantos, M.F., et al. Gliomas and the vascular fragility of the blood brain barrier. Front. Cell. Neurosci., 8, 2014, 418.
63. 63 Leten, C., Struys, T., Dresselaers, T., Himmelreich, U., In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models. J. Neurooncol. 119 (2014), 297–306.
64. 64 Candolfi, M., Curtin, J.F., Yagiz, K., Assi, H., Wibowo, M.K., Alzadeh, G.E., Foulad, D., Muhammad, A.K., Salehi, S., Keech, N., et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 13 (2011), 947–960.
65. 65 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008), 677–704.
66. 66 Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune Checkpoint Blockade in Cancer Therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
67. 67 Wainwright, D.A., Chang, A.L., Dey, M., Balyasnikova, I.V., Kim, C.K., Tobias, A., Cheng, Y., Kim, J.W., Qiao, J., Zhang, L., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 20 (2014), 5290–5301.
68. 68 Yang, J., Sanderson, N.S., Wawrowsky, K., Puntel, M., Castro, M.G., Lowenstein, P.R., Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc. Natl. Acad. Sci. USA 107 (2010), 4716–4721.
69. 69 Mineharu, Y., Kamran, N., Lowenstein, P.R., Castro, M.G., Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol. Cancer Ther. 13 (2014), 3024–3036.